IMPORTANCE Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease.
A utosomal recessive Stargardt macular dystrophy (STGD1; OMIM 248200) is the most common form of juvenile macular degeneration and is caused by mutations in ABCA4 (OMIM 601691).
1,2 Several treatment trials, including stem cell therapy, gene therapy, and medical therapy, are in early clinical phase trials. 2, 3 Visual acuity appears to be inadequate to capture the disease progression in STGD1 for most patients. 4 The multicenter Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were therefore designed to characterize the natural history of progression and to establish sensitive and meaningful end points for interventional trials. 5 From the perspective of the US Food and Drug Administration, the rate or extent of the anatomical progression of atrophy, similar to geographical atrophy secondary to age-related macular degeneration, can be such a possible end point beyond visual acuity. 6 Fundus autofluorescence (FAF) imaging is well established in clinical practice as a convenient, fast, and noninvasive imaging procedure, and has been shown to identify and delineate areas of atrophy in STGD1. 7, 8 Furthermore, FAF has been demonstrated to allow tracking disease progression successfully in smaller cohorts of patients with STGD1 at single centers.
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The purpose of this study is to report the growth rates of atrophic lesions as determined by FAF as the primary outcome measure in the retrospective ProgStar study.
Methods
The design, inclusion and exclusion criteria, and patients of the retrospective ProgStar study were described in detail previously 5 ; the ProgStar studies were designed between August 8, 2012, and March 14, 2013 . Briefly, patients with at least 2 pathogenic mutations in the ABCA4 gene (or 1 mutation, but with the clinical phenotype of flecks at the level of the retinal pigment epithelium typical for STGD1) were eligible. A total of 251 patients aged 6 years or older at baseline, harboring diseasecausing variants in ABCA4, enrolled in the study from 9 centers between August 2, 2013, and December 12, 2014 . Minimum age was 6 years at the most recent visit. The minimum total observation period was 24 months, and the maximum period between single visits was 60 months. Inclusion criteria required the presence of a well-defined atrophic lesion at the most recent visit of at least 300 μm in diameter; the area of all lesions together must total 12 mm 2 or less and must represent no more than 5 disc areas in at least 1 eye. The presence of an atrophic lesion at the first retrospective visit was not required. Fundus autofluorescence images were eligible if they were obtained with a Heidelberg Engineering device such as the Heidelberg Retina Angiograph 2 or Heidelberg Spectralis (excitation light, 488 nm; barrier filter, 500 nm). Fundus autofluorescence images were graded at a central reading center (eAppendix in the Supplement). The field of view was 30°× 30°in 367 of 386 eyes (95.1%), 35°× 35°and 20°× 20°in 2 eyes each (0.5%), 34°× 30°in 1 eye (0.3%), and 55°in diameter in 10 eyes (2.6%). The magnification could not be graded in 4 eyes. Fundus autofluorescence image grading protocols were developed within the ProgStar consortium based on preliminary discussions and previous publications on FAF imaging in STGD1 10 and were validated in a preliminary pilot projects.
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Qualitative Grading Parameters
Qualitative grading parameters included the absence or presence of flecks both within and outside the arcades, the presence of increased FAF at the edge of a lesion of decreased FAF, and FAF background uniformity based on a previously published grading scheme 10 : a homogeneous background signal was defined as an even distribution of background autofluorescence, while a heterogeneous background signal was defined as widespread small foci of increased or reduced autofluorescence.
Quantitative Grading Parameters
Different types of decreased areas of autofluorescence were defined based on the qualitative measures of darkness ( Figure 1) 
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: definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence (QDAF). The optic
Key Points
Question What is the growth rate of atrophic lesions in patients with Stargardt disease?
Findings In this multicenter cohort study, mean progression of definitely decreased autofluorescence lesions was 0.51 mm 2 /y, and of total decreased fundus autofluorescence was 0.35 mm 2 /y. Rates of progression depended on initial lesion size.
Meaning
The growth rate of atrophic lesions as determined by fundus autofluorescence in patients with Stargardt disease may be a suitable outcome measure for treatment trials.
nerve head (or, if not present in the image, the vessels) was the reference for 100% blackness on the gray scale. The decreased autofluorescence pattern had to appear darker than background gray level and the lesion diameter had to be 125 μm or more. Definitely decreased autofluorescence was more than 90% black in reference to the optic nerve head, and questionably decreased autofluorescence was 50% to 90% black.
The area of the respective lesions was semiautomatically evaluated using the RegionFinder module of the Heidelberg Eye Explorer (Heidelberg Engineering) with grading conventions previously described and provided in the eAppendix in the Supplement. 5, [15] [16] [17] [18] 
Statistical Analysis
The yearly increase in the size of DDAF or total lesion area (sum of DDAF and QDAF) was assessed using eyes in which the specific lesion type was present in at least 2 visits. Exploratory inspection of lesion growth over time showed a strong dependency on lesion size at the first visit. For both DDAF and total lesion area, stratified analysis by lesion size at first visit was performed using the 33rd and 66th percentiles of the distribution of lesion size to create 3 categories.
The yearly progression rate was similar in the first 2 categories; hence, the analyses presented here use only a single cutoff: for the DDAF baseline area of 1.92 mm 2 or less (66th percentile) and greater than 1.92 mm 2 and for the total lesion size (DDAF and QDAF) baseline total area of 2.50 mm 2 or less (66th percentile) and baseline total area greater than 2.50 mm 2 ( Figure 2) . Linear mixed models stratified by lesion size, with time as the independent variable, were used to estimate the yearly change for each outcome. The models include random effects for the intercept, the slope for time, and the eye. Parallel analyses using the square root of the area were also performed but did not eliminate the dependency of progression on initial lesion size. Statistical analyses were conducted using SAS, version 9.3 (SAS Institute Inc) and R project for statistical computing, version 2.15.1 (Institute for Statistics and Mathematics).
Results
A total of 251 patients were enrolled at 9 centers in the United States and Europe between August 2, 2013, and December 12, 2014 ; FAF images for at least 2 visits were available for 217 patients, of which 173 patients (79.7%) were enrolled with both eyes and 44 (20.3%) with 1 eye, for a total of 390 study eyes. Images of 4 eyes of 2 patients had to be excluded during the grading process owing to low quality. Images of 386 study eyes of 215 patients with a total of 1075 eye visits (mean, 2.8 visits per eye) had atrophic lesions present on at least 2 visits. Of these patients, 146 (67.9%) were white and 126 (58.6%) were female, the mean (SD) age was 29.9 (14.7) years and the mean (SD) age of onset of symptoms was 21.9 (13.3) years, and lesions were graded for 2 study visits (156 eyes), 3 study visits (173 eyes), or 4 study visits (57 eyes) (eTable 1 in the Supplement). The mean (SD) follow-up time was 3.9 (1.6) years (range, 0.44-12.1 years). eTable 1 in the Supplement summarizes patient characteristics. For DDAF analyses, 90 of 133 patients (67.7%) contributed both eyes to analyses, and for any lesion, 170 of 215 patients (79.1%) contributed both eyes (eTable 1 in the Supplement). The presence or absence of the qualitative grading parameters of flecks, increased FAF at the lesion edge of DDAF lesions, and background uniformity are presented in Table 1 .
Characteristics of Eyes With DDAF
A total of 224 of the 386 eyes (58.0%) showed at least 1 lesion of DDAF that could be tracked over at least 2 study visits during the follow-up period, either alone or in combination with 
Estimated Growth Rates of Lesions of DDAF
Overall, mean progression of DDAF was 0.51 mm 2 /y (95% CI, 0.42-0.61 mm 2 /y). However, the growth rates were strongly dependent on initial lesion size. Thus, it is important to take into consideration initial lesion size when reporting progression rates in terms of mm 2 per year. As described in the Methods, we analyzed the growth rate within lesion size, using the 66th percentile of the distribution of lesion size at baseline (1.92 mm 2 ) to divide the cohort into subgroups. The estimated growth rates in eyes with lesion sizes of 1.92 mm 2 After stratifying by lesion size, neither duration of disease (<10 vs ≥10 years) nor background heterogeneity (homogeneous vs heterogeneous background) was associated with differences in progression ( Table 2) . Within lesion size categories, growth rates were age dependent, with lower rates observed in the younger age group. However, stratification for the number of foci of DDAF revealed differences, with lower growth rates for unifocal lesions regardless of lesion size at baseline.
Characteristics of Eyes With Any Lesion (DDAF and QDAF)
Overall mean (SD) lesion size in 386 eyes of decreased areas of autofluorescence (sum of DDAF and QDAF) at the first visit included for analysis was 2. ; P < .001), although, as noted for DDAF, because all heterogeneous eyes had flecks, it was not possible to determine which of the characteristics was more associated with larger area.
Estimated Growth Rates of Lesions of Total Area of Decreased Autofluorescence Over Time
Mean progression of total decreased FAF was 0.35 mm 2 /y (95% CI, 0.28-0.43 mm 2 /y). As described in the Methods, the following 2 subgroups were defined using the 66th percentile of the distribution of lesion size at first visit: eyes with lesion areas of 2.50 mm 2 or less and eyes with lesion areas greater than 2.50 There was no difference in growth rate by duration of symptoms or background heterogeneity. However, in eyes with growth of lesion areas of 2.50 mm 2 or less, rates were age dependent, with higher rates in patients 30 years of age or older ( Table 2 ).
Discussion
Other natural history studies and interventional trials have reported progression rates that suggest wide variation in starting sizes of lesions. [10] [11] [12] [19] [20] [21] [22] With a mean (SD) follow up of 3.9
(1.6) years, we found a yearly progression for both DDAF and total area (DDAF and QDAF). The growth of these lesions depended on the baseline lesion, with greater rates seen in lesions with a larger initial size. Thus, we think it is not accurate to report an overall growth rate, as the rate will depend on the starting size, which is an important point for clinicians in determining the rate of progression for their patients. The choice of model to characterize the growth rates was challenging. We tried different models, including linear, log linear, and square root transformation. However, to estimate yearly progression rates, linear mixed models stratified by initial lesion size showed the best fit, and characterized the rate with reasonable complexity. However, we provide addition results using the square root transformation of the lesion area as the outcome (eTable 3 in the Supplement), as previously done in age-related macular degeneration.
23
In ProgStar, we defined another type of reduced, although not absent, autofluorescence as QDAF 24 : previous studies either defined 2 types called absent FAF and areas of abnormal FAF, 25 or profound hypofluorescence vs less profound hypoautofluorescence. 24 In these studies, a semiquantitative approach was used by analyzing the FAF images using levels of gray. One limitation of our study is that the grading did not permit use of an absolute quantitative gray scale. This limitation may have contributed to the variability in the grading. One challenge when grading the lesions of QDAF is the macular pigment that, when present, could be misinterpreted as reduced FAF. 26 To counteract this confounder, especially in fovealsparing cases, the graders used the constraint tool to exclude the foveal center from measurements, and could consult infrared images obtained at the same visit (if available). If deemed necessary, graders could consult images from a previous visit, although this was discouraged until completion of an independent assessment of the current images. However, it may have biased the grading process to an unknown extent. Lesions of QDAF may be of interest for future therapeutic intervention because tissue may still be amenable to rescue. In exploratory analyses, the areas of QDAF showed 3 different patterns in respect to lesion size: increase, stable, or decrease. The observation that areas of decreased autofluorescence tend to be unstable and can vary with respect to the temporal sequence of autofluorescence changes has been previously described. 24, 27 Questionably decreased autofluorescence may be considered a transition state between healthy retina and later stages of the disease process (ie, DDAF); hence, we report the total area of lesions (sum of DDAF and QDAF). Future analysis and correlation of FAF with findings in spectral domain optical coherence tomography as part of ProgStar will shed further light on the temporal sequence. Previous reports have found a higher rate of lesion growth for all eyes with a heterogeneous background compared with a homogeneous background. 10, 12 However, these studies did not adjust for mean lesion size at baseline, and while we found an association of heterogeneous background with mean area at baseline, we did not find an association with progression of lesions. If eyes with a heterogeneous background represent a more advanced stage of the disease with larger lesions, then by adjusting for lesion size, we have adjusted out the effect of the background heterogeneity. Further comparisons of our results to the ones from previous studies are limited owing to differences including image acquisition and analysis, 11 missing confirmation of disease-causing mutations, 12 and categorization of phenotypes and statistical methods applied. 10 However, similar characteristics are observed with geographic atrophy lesions in age-related macular degeneration, such as faster rates of progression in multifocal lesions, 28 even though the mechanisms in the 2 diseases are incompletely understood and may be very different, as illustrated by different growth rates when comparing late-onset STGD1 with agerelated macular degeneration.
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There is evidence from several studies that the FAF signal originates from lipofuscin in retinal pigment epithelium cells and that excessive accumulation of lipofuscin causes an increased FAF 30 ; higher concentrations of lipofuscin are also thought to have harmful effects on normal cell function. 31 We therefore investigated the possible influence on rates of progression. There was no association of area of lesion with the presence of increased FAF at the lesion edge for DDAF. We did not quantify the extent of increased FAF, which may explain some of this difference. Also, Smith et al 24 reported that focally increased autofluorescence deposits with FAF levels elevated above the initial macular background were less likely in the short term (2 years) to transform to geographic atrophy than were any random areas, suggesting additional mechanisms beyond direct lipofuscin toxicity. We did find that flecks and a heterogeneous background were associated with lesion area for DDAF and total area, but were not associated with progression. Our data suggest that the flecks and heterogeneous background develop with, rather than precede, the growth of the lesion. Our prospective study will be able to confirm or refute this hypothesis.
Limitations and Strengths
Our study has inherent limitations based on the retrospective design, including absence of standardization of image acquisition both across and within participating sites, and data collected on the basis of medical record review. However, a strength is the longer observational period in this large cohort, as is the multicenter setting that provided data from a broad range of patients. Another strength is the use of standardized grading procedures by certified, experienced reading center graders.
Conclusions
We have shown that tracking the size of lesions of DDAF can be a useful tool to monitor disease progression in STGD1, while for earlier stages of STGD1 exhibiting lesions of QDAF only, structural analysis derived from spectral domain optical coherence tomography might be more reliable. 25, 26, 32 Furthermore, growth rates depended on initial lesion size, and this should be accounted for in upcoming interventional trials that aim to slow down disease progression. 
eAppendix. Methods
Grading of FAF images
De identified and anonymized FAF images of eligible patients and visits were sent by the participating sites to the reading center RC Doheny )maging Reading Center Doheny Eye 
Quantitative grading
The area of the respective lesions was semi automatically evaluated using the RegionFinder module of the (eidelberg Eye Explorer TM (eidelberg Engineering (eidelberg Germany with grading conventions shadow correction was applied when the FAF images were unevenly or inadequately illuminated algorithm growth power was adjusted and refined manually until the region fully captured the area of decreased FAF manual line circles contours or free hand constraints were used as needed to distinguish lesion boundaries and exclude vascular structures in case of confluence of central and peripapillary atrophy an approximately vertical line constraint had to be set at the narrowest part bridge with atrophy quantification including only atrophy temporal to the constraint and disregarding atrophy nasal to the constraint For multifocal lesions the sum of all areas of DAF within each subtype was calculated Number of foci of DDAF was recorded and graded as either unifocal n or multifocal n As the distinction between normal foveal DAF and abnormal DAF can be challenging when American Medical Association All rights reserved using FAF images alone additional infrared reflectance )R fundus images if provided could be used to add supplementary information particularly when confirming the presence of foveal atrophy FAF images were independently reviewed by certified graders At least of the graders was a senior level grader Any assessments where initial answers were not concordant underwent adjudication )f consensus could not be reached between adjudicating graders the final answer was determined by a reading center investigator )n single visits of patients eye visits of eyes images could not be opened and analyzed using the RegionFinder tool due to image size constraints )n these patients grading was performed using a planimetric grading software program GRADOR developed by the RC which demonstrates good agreement and equivalence 
